PLK2 (Polo-like kinase 2) is a member of the polo-like kinase family of serine/threonine protein kinases that play essential roles in cell cycle regulation, centrosome duplication, and cellular stress responses. In the nervous system, PLK2 has emerged as an important regulator of synaptic function and has been implicated in the pathogenesis of neurodegenerative diseases including Parkinson's disease (PD) and Alzheimer's disease (AD) [1][2]. Unlike other polo-like kinases, PLK2 is expressed at high levels in post-mitotic neurons where it performs specialized functions related to synaptic plasticity and protein quality control [3].
The unique neuronal functions of PLK2 stem from its regulation by synaptic activity and its involvement in phosphorylation of proteins implicated in neurodegeneration, including alpha-synuclein and tau [4].
¶ Gene and Protein Structure
The PLK2 gene (also known as SNK) is located on chromosome 5q12.1 in humans and encodes a protein of approximately 71 kDa. The gene contains a kinase domain in its N-terminus and a C-terminal polo-box domain (PBD) that mediates protein-protein interactions [5].
¶ Protein Domain Architecture
PLK2 contains several functional domains:
- Kinase domain (aa 1-300): Catalytic domain with serine/threonine kinase activity
- Polo-box domain (aa 400-650): Tandem polo boxes that recognize phosphorylated serine/threonine motifs
- Polo-box domain (aa 520-650): Second polo-box involved in substrate specificity
- Nuclear localization signals: Regulate subcellular distribution
The polo-box domain gives PLK2 unique substrate specificity, allowing it to recognize proteins containing phospho-Ser/Thr-Pro motifs [6].
In proliferating cells, PLK2 functions as a cell cycle regulator:
- G1/S transition: PLK2 is induced early in S phase and promotes cell cycle progression
- Centrosome duplication: PLK2 phosphorylates components of the centrosome to ensure proper duplication
- ** mitotic entry**: PLK2 activity contributes to activation of CDK1/cyclin B [7]
In neurons, PLK2 performs specialized synaptic functions:
- Synaptic vesicle dynamics: PLK2 phosphorylates proteins involved in synaptic vesicle cycling
- Synaptic plasticity: Activity-dependent PLK2 expression modulates long-term synaptic changes
- Dendritic spine morphology: PLK2 regulates spine shape through phosphorylation of cytoskeletal proteins [8]
PLK2 contributes to cellular protein quality control mechanisms:
- Autophagy regulation: PLK2 phosphorylates autophagy receptors and initiation complexes
- Proteasomal degradation: PLK2 targets proteins for ubiquitin-dependent degradation
- Aggresome formation: PLK2 participates in aggresome formation for aggregate clearance [9]
PLK2 has emerged as an important kinase in PD pathogenesis:
- Alpha-synuclein phosphorylation: PLK2 phosphorylates alpha-synuclein at Ser129 (Ser129-P), a modification that constitutes a major component of Lewy bodies. Over 90% of Lewy body inclusions contain Ser129-phosphorylated alpha-synuclein [10].
- Protein aggregation: PLK2-mediated phosphorylation can promote alpha-synuclein aggregation, creating a feed-forward pathological loop [11].
- Genetic associations: Polymorphisms in the PLK2 gene have been associated with PD risk in some populations [12].
- Dopaminergic neuron survival: PLK2 activity affects survival of dopaminergic neurons, the cells lost in PD [13].
- Tau phosphorylation: PLK2 can phosphorylate tau at several AD-relevant sites, potentially contributing to neurofibrillary tangle formation [14].
- Synaptic dysfunction: PLK2-mediated phosphorylation of synaptic proteins may contribute to synaptic loss in AD [15].
- Beta-amyloid effects: Aβ exposure can alter PLK2 expression and activity [16].
- Huntington's disease: PLK2 phosphorylates mutant huntingtin protein and may influence aggregation [17]
- Amyotrophic lateral sclerosis: Altered PLK2 activity has been observed in ALS models [18]
Several PLK2-selective inhibitors have been developed:
- Small molecule inhibitors: Compounds like BI 2536 and GSK2126458 inhibit PLK2 with varying selectivity
- Clinical challenges: PLK2 inhibitors affect cell division, limiting therapeutic window in neurons
- Neuron-specific approaches: Activity-dependent delivery or prodrug strategies may improve selectivity [19]
Targeting the PLK2-alpha-synuclein axis:
- Kinase inhibitors: Reducing Ser129 phosphorylation may decrease aggregation
- Combination approaches: PLK2 inhibition combined with other therapeutic strategies [20]
PLK2 expression is regulated at multiple levels:
- Immediate-early gene: PLK2 is induced by neuronal activity via transcription factors
- Epigenetic control: PLK2 promoter has activity-dependent epigenetic modifications
- MicroRNA regulation: miRNAs including miR-124 target PLK2 mRNA [21]
PLK2 phosphorylates numerous substrates:
- Alpha-synuclein: Ser129 - major PD-relevant site
- Tau: Multiple sites including Thr181, Ser202, Ser396
- Centrin: Centrosome function
- Myt1: Cell cycle regulation
- Syntaxin: Synaptic vesicle trafficking [22]
PLK2 interacts with various proteins:
- 14-3-3 proteins: Scaffold PLK2 signaling complexes
- Pin1: Prolyl isomerase that may regulate PLK2 function
- Hsp90: Chaperone that stabilizes PLK2
- Ubiquitin ligases: Coordinate PLK2 turnover [23]
Additional evidence sources: